MedTrace Logo

An Effectiveness, Safety, and Microbiology Study of Doripenem in Patients With Nosocomial (Hospital-acquired) Pneumonia

NCT00502801 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 185

Last updated 2013-09-25

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the effectiveness and safety of doripenem monohydrate in the treatment of patients with nosocomial (hospital-acquired) pneumonia.

Conditions

  • Pneumonia
  • Bacterial Pneumonia
  • Ventilator-Associated Pneumonia
  • Infections, Nosocomial

Interventions

DRUG

doripenem

1g i.v. infused over 4 hours every 8 hours for 8 to 14 days

Sponsors & Collaborators

  • PriCara, Unit of Ortho-McNeil, Inc.

    lead INDUSTRY

Principal Investigators

  • PriCara, Unit of Ortho-McNeil, Inc. Clinical Trial · PriCara, Unit of Ortho-McNeil, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • United States
  • Argentina
  • Canada
  • Chile
  • Croatia
  • France
  • India
  • Russia
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00502801 on ClinicalTrials.gov